Business Wire- November 16, 2007

Introduction

Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.

Scope

- Current epidemiology of HIV in the six major markets, including prevalence, diagnosis rates and patients split by line of therapy and drug regimens.

- A detailed examination of the patient numbers on each line of therapy, their drug regimens and preferences.

- Evaluation of the factors determining prescription choices and their respective level of influence.

- An assessment of the perception of new products in development and of key unmet needs within HIV.

Highlights

In the US and M5EU the total number of people living with HIV is continuing to increase. According to the physician survey, the total number of diagnosed patients across the 6MM is 1.1 million, of which 18% are treatment-na ve and approx. 800.000 are currently receiving therapy.

The complexity of HAART begins to increase as patients progress to later stages of therapy, with regimens consisting of up to 6 different drugs. Treatment also becomes much more individualized: This research shows that the top 5 most popular regimens selected by physicians account for only 13% of patients in salvage therapy.

Prescription choice is largely driven by patient and product-specific qualities, but the influence of these issues varies according to line of therapy. Efficacy and resistance profile exert an increasing influence as the patient becomes more treatment-experienced.

Reasons to Purchase

- Identify the key factors underlying prescription choice for treatment of HIV.

- Examine the current unmet needs in the HIV market and identify opportunities for new product development.

- Enhance your commercial positioning through an improved understanding of the HIV market dynamics.

Content Outline:

About Our Healthcare

About The Infectious Diseases And Respiratory Pharmaceutical Analysis Team

Chapter 1 Executive Summary

Chapter 2 Introduction And Scope

Chapter 3 Country Treatment Trees

Chapter 4 Epidemiology And Patient Segmentation

Chapter 5 Diagnosis And Treatment Rates

Chapter 6 Treatment Options And Trends

Chapter 7 Prescribing Influences And Brand Assessment

Chapter 8 Improving Treatment Outcomes And New Product Development

Bibliography

Appendix A

Appendix B

List Of Tables

List of Figures

Products Mentioned:

- Awareness

- GS-9137 (elvitegravir)

- MK-0518 (raltegravir)

- Selzentry/Celsentri (maraviroc)

- TMC125 and TMC278

- Vicriviroc

For more information visit http://www.researchandmarkets.com/reports/c74552.

Source: Datamonitor

071116
BW071118

Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .